EVALUATION OF KIDNEY FUNCTION IN AN ELDERLY PATIENT WITH ACUTE MYELOBLASTIC LEUKEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT

Oncologia i radiologia Kazakhstana Pub Date : 2023-03-31 DOI:10.52532/2521-6414-2023-1-67-46-49

A. Murzakhmetova, A. Meiramova, A. Issilbayeva, B. Abdahina, E. Omralina, B. Ainabekova

{"title":"EVALUATION OF KIDNEY FUNCTION IN AN ELDERLY PATIENT WITH ACUTE MYELOBLASTIC LEUKEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT","authors":"A. Murzakhmetova, A. Meiramova, A. Issilbayeva, B. Abdahina, E. Omralina, B. Ainabekova","doi":"10.52532/2521-6414-2023-1-67-46-49","DOIUrl":null,"url":null,"abstract":"Relevance: Kidney functions in treating acute myeloblastic leukemia (AML) undergo serious effects, especially in elderly patients. Chemotherapeutic drugs used to prepare for hematopoietic stem cell transplantation (HSCT) inevitably affect elderly patients’ kidney function. Moreover, involutive changes in the kidneys can physiologically decrease kidney function. \nThe study aimed to evaluate kidney function in an elderly patient with AML after HSCT. \nMethods: The article describes a clinical case of AML in an elderly patient who underwent allogeneic HSCT. \nResults: We analyzed the dynamics of the functional state from the moment of registration of AML to +100 days after HSCT. During the entire follow-up period, we did not detect any renal dysfunction in the elderly patient. Despite the HSCT and the effects of nephrotoxic drugs in an elderly patient + 100 days after HSCT, kidney function was preserved. \nConclusion: The described case highlights the importance of maintaining renal function in elderly patients after HSCT and long-term renal monitoring.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":"312 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologia i radiologia Kazakhstana","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52532/2521-6414-2023-1-67-46-49","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Relevance: Kidney functions in treating acute myeloblastic leukemia (AML) undergo serious effects, especially in elderly patients. Chemotherapeutic drugs used to prepare for hematopoietic stem cell transplantation (HSCT) inevitably affect elderly patients’ kidney function. Moreover, involutive changes in the kidneys can physiologically decrease kidney function. The study aimed to evaluate kidney function in an elderly patient with AML after HSCT. Methods: The article describes a clinical case of AML in an elderly patient who underwent allogeneic HSCT. Results: We analyzed the dynamics of the functional state from the moment of registration of AML to +100 days after HSCT. During the entire follow-up period, we did not detect any renal dysfunction in the elderly patient. Despite the HSCT and the effects of nephrotoxic drugs in an elderly patient + 100 days after HSCT, kidney function was preserved. Conclusion: The described case highlights the importance of maintaining renal function in elderly patients after HSCT and long-term renal monitoring.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

老年急性髓细胞白血病患者造血干细胞移植后肾功能的评价:1例报告

相关性:急性髓母细胞白血病(AML)治疗中肾功能受到严重影响，尤其是老年患者。用于准备造血干细胞移植(HSCT)的化疗药物不可避免地影响老年患者的肾功能。此外，肾脏的渐进性变化可在生理上降低肾功能。该研究旨在评估一名老年AML患者HSCT后的肾功能。方法:本文描述了一例接受同种异体造血干细胞移植的老年AML患者的临床病例。结果:我们分析了从AML登记到HSCT后+100天的功能状态动态。在整个随访期间，我们未发现老年患者出现任何肾功能障碍。一位老年患者在移植后100天，尽管接受了移植和肾毒性药物的影响，但肾功能得以保留。结论:该病例强调了老年HSCT术后维持肾功能和长期肾脏监测的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oncologia i radiologia Kazakhstana

自引率

0.00%

发文量